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Abstract
Background: Obesity and commonly associated comorbidities are known risk factors for the development of
infections. However, the intensity and duration of antimicrobial treatment are rarely conditioned on body mass
index (BMI). In particular, the influence of obesity on failure of antimicrobial treatment for intra-abdominal
infection (IAI) remains unknown. We hypothesized that obesity is associated with recurrent infectious com-
plications in patients treated for IAI.
Methods: Five hundred eighteen patients randomized to treatment in the Surgical Infection Society Study to
Optimize Peritoneal Infection Therapy (STOP-IT) trial were evaluated. Patients were stratified by obese (BMI
‡30) versus non-obese (BMI‡30) status. Descriptive comparisons were performed using Chi-square test, Fisher
exact test, or Wilcoxon rank-sum tests as appropriate. Multivariable logistic regression using a priori selected
variables was performed to assess the independent association between obesity and treatment failure in patients
with IAI.
Results: Overall, 198 (38.3%) of patients were obese (BMI ‡30) versus 319 (61.7%) who were non-obese. Mean
antibiotic d and total hospital d were similar between both groups. Unadjusted outcomes of surgical site infection
(9.1% vs. 6.9%, p= 0.36), recurrent intra-abdominal infection (16.2% vs. 13.8, p= 0.46), death (1.0% vs. 0.9%,
p= 1.0), and a composite of all complications (25.3% vs. 19.8%, p= 0.14) were also similar between both groups.
After controlling for appropriate demographics, comorbidities, severity of illness, treatment group, and duration
of antimicrobial therapy, obesity was not independently associated with treatment failure (c-statistic: 0.64).
Conclusions: Obesity is not associated with antimicrobial treatment failure among patients with IAI. These
results suggest that obesity may not independently influence the need for longer duration of antimicrobial
therapy in treatment of IAI versus non-obese patients.
Obesity affects a large and increasing percentage ofthe American population, with more than one in three
American adults considered obese. Unfortunately, little is
known about the implications of obesity on the clinical effi-
cacy of most pharmaceutical agents [1].With few exceptions,
dosing guidelines for pharmaceuticals, including most anti-
microbial agents, do not advise weight-based dosing adjust-
ments. Although a growing number of studies have identified
altered pharmacodynamics (PD) and pharmacokinetic (PK)
parameters in various populations of obese patients, few drug
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studies are designed to evaluate potentially unique dosing
needs for the obese population [2]. Similarly, few studies
have been conducted among surgical patients with intra-
abdominal infection to evaluate whether treatment failure
occurs at greater rates among the obese with conventional
dosing strategies versus normal weight comparators.
The successful treatment of infection balances the need to
achieve therapeutic serumand tissue antibiotic concentrations
to facilitate the eradication of pathogens against the risks of
pharmacologic toxicity. In short, insufficient dosing risks
treatment failure, whereas more aggressive dosing strategies
may increase the risk of toxicity. The parameters that influ-
ence serum antimicrobial concentrations such as absorption,
volume of distribution, metabolism, and excretion, among
others, may vary greatly among individual patients as a result
of underlying disease or an acute physiologic disturbance.
How the obese body habitus further compounds these com-
plex interactions largely remains unclear for most antimi-
crobial agents, as well as most other prescriptionmedications.
We sought to evaluate whether obesity is associated with
antimicrobial treatment failure for intra-abdominal infection,
which could suggest that standard antimicrobial dosing
strategies are insufficient in obese patients. Using data from
the recently completed Study to Optimize Peritoneal Infec-
tion Therapy (STOP-IT) trial [3], we hypothesized that
obesity is associated with increased treatment failure for IAI
versus normal weight comparators.
Patients and Methods
Data source
The STOP-IT trial was an investigator-initiated, open-label,
multi-center trial conducted to define the optimal duration of
antimicrobial therapy in patients after adequate source control
of complicated IAI (cIAI). Five hundred eighteen patientswere
enrolled at 23 sites in the United States and Canada over a 5-y
study period. The study was coordinated through the Surgical
Infection Society and the University of Virginia. Institutional
Review Boards at all participating sites approved the study.
Patient characteristics
Eligible patients were 16 y of age or older with cIAI and
either fever (temperature ‡38.0C), leukocytosis (peripheral
white blood cell [WBC] count >11,000/mL), or gastrointes-
tinal dysfunction because of IAI precluding intake of more
than half of their normal diet, and had undergone either per-
cutaneous or surgical intervention to achieve source control
[3]. Source control is recognized as an essential component of
treatment for cIAI. For the purposes of STOP-IT, source
control was defined as elimination of infectious foci, control
of factors that promote ongoing infection, and correction or
control of anatomic derangements to restore normal physio-
logic function. Patients with non-infectious, inflammatory
causes of peritonitis, such as non-perforated cholecystitis or
necrotic but non-perforated bowel, were excluded.
Statistical analysis
Data analyses were designed to test the null hypothesis that
obesity, defined as body mass index (BMI) ‡30, is not as-
sociated with treatment failure—defined as a composite
outcome of recurrent IAI, surgical site infection, or death—in
the study population. Additional analyses were performed
using thresholds to define obesity of BMI ‡35 and BMI ‡40.
Statistical significance was determined using the standard
alpha value of <0.05. All data analyses were performed using
the open-source programming language R and user interface
RStudio (RStudio, Boston, Massachusetts), as well as open-
source packages [4–8].
Descriptive, univariate statistics were utilized to charac-
terize baseline demographic characteristics, co-morbid dis-
ease states, treatment characteristics, and outcomes, stratified
by obesity status. Additional comparisons were performed to
assess treatment failures by antibiotic class, again stratified
by obesity status.
Continuous data are reported as median values [inter-
quartile range] and were compared using the Wilcoxon rank-
sum test. Categorical values are reported as a percentage of
the total population of each group, and were compared using
Fisher exact or Chi-square tests where appropriate.
Multivariable logistic regression was performed to deter-
mine associations with treatment failure and included a
combination of a priori selected variables and others identified
in univariate analysis. Modeled factor likelihood ratios (Wald
2 statistic)were utilized to estimate the predictive strength and
relative contribution of each covariate with the odds of
treatment failure. Results are reported as adjusted odds ratios
with 95% confidence intervals. Model performance was as-
sessed using the calculated Area Under the Receiver Oper-
ating Characteristic Curve. All calculated test statistics were
used to derive reported two-tailed p values.
Results
Patient demographics and disease characteristics are pre-
sented in Table 1, stratified by obesity status. Five hundred
seventeen patients were included for analysis after exclusion
of one study participant because of missing data. Mean BMI
for the entire study population was 29.0– 8.8, 23.8– 3.5 for
non-obese patients, and 37.3– 8.3 for obese patients. There
were few other differences between obese and non-obese pa-
tients. Not surprisingly, diabetes mellitus was observed more
frequently among obese patients, as was insulin-dependent
diabetesmellitus. The incidence of chronic kidney diseasewas
not substantially different in obese versus non-obese patients.
Characteristics of cIAI affecting patients and disease se-
verity, as well as original STOP-IT treatment group assign-
ments (i.e., control group vs. experimental), are presented in
Table 2. Patients were evenly distributed between study
groups by weight class and demonstrated comparable se-
verity of illness scores. Likewise, the sites of IAI infection
were similarly distributed among obese and non-obese pa-
tients. Overall, total antibiotic d and total length of stay did
not differ between obese and non-obese patients.
Procedures used to gain source control and clinical out-
comes are detailed in Table 3. Although the composite out-
come of surgical site infection, recurrent intra-abdominal
infection, or death, approached or exceeded 20% in both
groups, these outcomes were comparable between obese and
non-obese patients.
Bivariate analysis of the rates of treatment failure by
antibiotic class, as measured by the composite outcome, is
presented in Table 4, stratified by obesity status. b-lactam-
penicillins were the antibiotic most commonly utilized
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as part of the antibiotic regimen for study participants.
Treatment failure rates did not differ in obese patients for
any antibiotic class, with the exception of the subset of
patients that received triazoles, for which failure rates
among the obese exceeded those of non-obese patients.
This relation, however, was not observed in subsequent
analyses using thresholds to define obesity of BMI ‡35 and
BMI ‡40.
The results of multivariable logistic regression to deter-
mine the association of obesity with treatment failure and
Table 1. Patient Demographics and Disease Characteristics Stratified by Obesity Status
Risk factor n Non-obese Obese p
Total 517 319 (61.7%) 198 (38.3%)
Age 53 [39–65] 53 [42–62] 0.91
Body mass index 24.0 [22–27] 35.0 [31–40] <0.001
Female 229 41.2 % 48.5 % 0.13
White 403 76.5 % 80.3 % 0.31
Black 94 18.2 % 18.2 % 1.00
American Indian/Alaskan Native 3 0.63% 0.51% 0.86
Asian 11 3.50% 0.0 % 0.01
Hispanic 35 0.1 % 0.1 % 0.35
Comorbidities
Cardiac disease 70 11.9 % 16.2 % 0.17
Cerebrovascular disease 19 3.5 % 4.0 % 0.73
Peripheral vascular disease 15 3.1 % 2.5 % 0.69
Diabetes mellitus (total) 78 11.9 % 20.2 % 0.01
IDDM 36 4.7 % 10.6 % 0.01
NIDDM 42 7.2 % 9.6 % 0.33
Steroid use 31 3.8 % 2.0 % 0.27
Inflammatory bowel disease 53 12.2 % 7.1 % 0.06
Malignant disease 59 13.5 % 8.1 % 0.06
Chronic kidney disease 25 6.0 % 3.0 % 0.13
Dialysis dependence 9 1.9 % 1.5 % 1.00
Chronic liver disease 17 3.8 % 2.5 % 0.44
Chronic pulmonary disease 28 6.3 % 4.0 % 0.28
Red blood cell transfusion since admission 43 8.8 % 7.6 % 0.63
IDDM= Insulin-dependent diabetes mellitus; NIDDM=Non-insulin-dependent diabetes mellitus.
Table 2. Disease Characteristics Stratified by Obesity Status
Risk factor n Non-obese Obese p
APACHE-II score 517 9.0 [ 6–14] 9.0 [ 5–13] 0.37
Maximum white blood cell count 517 15 [11–20] 16.2 [13–19] 0.12
Maximum temperature 517 37.5 [37–38] 37.8 [77–38] 0.01
Total antibiotic days 517 5.0 [ 4–10] 5.0 [ 4–8] 0.12
Total hospital days 517 6.0 [ 4–11] 7.0 [ 4–10] 0.34
STOP-IT study group 0.52
4 d 257 48.5% 51.5%
Clinical resolution 260 51.4% 48.5%
Setting of IAI
Community-acquired 321 61.4% 63.1% 0.70
Healthcare-associated 127 24.5% 24.8% 0.94
Hospital-acquired 69 14.1% 12.1% 0.52
Organ site of IAI
Colon or rectum 177 37.3% 29.3% 0.06
Biliary tree including gallbladder 56 10.0% 12.1% 0.46
Duodenum 23 4.4% 4.6% 0.93
Small intestines 73 14.7% 13.1% 0.61
Esophagus 3 0.0% 1.5% 0.06
Stomach 31 5.3% 7.1% 0.42
Appendix 73 13.2% 15.7% 0.43
Pancreas 16 4.4% 1.0% 0.04
Liver 18 2.8% 4.6% 0.30
Abdominal wall surgical site 13 1.6% 4.0% 0.09
Other 34 6.3% 7.1% 0.72
IAI= Intra-abdominal infection.
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model performance are presented in Table 5, which suggest
that obesity is not associated with treatment failure in patients
with cIAI. Table 6 displays the association of obesity with
treatment failure for analyses performed using BMI thresh-
olds to define obesity of greater than or equal to 30, 35, and
40. None of these analyses identifies a substantial relation
between obesity and treatment failure. Complete results of
analyses performed using obesity thresholds of BMI ‡35 and
BMI ‡40 are available in supplementary Appendices A and
B, respectively.
Discussion
In this post-hoc subgroup analysis of the STOP-IT trial,
obesity was not associated with treatment failure for cIAIs, nor
were noteworthydifferences in treatment failure rates observed
across antibiotic classes. The present study provides reassur-
ance that the diverse antimicrobial regimens employed across
the 23 participating sites did not result in disproportionate
treatment failures among obese patients with cIAI. Similarly,
obesity was not found to be an independent predictor of treat-
ment failure in multivariable regression, although it ap-
proached significance when obesity was defined as BMI ‡30.
Importantly, patients in this study all underwent adequate
intervention to achieve cIAI source control, and the principal
findings of the STOP-IT trial were non-inferiority of 4 d of
antibiotics versus an extended course based on clinical
parameters. Thus, our findings should only be considered in
the context of this specific patient population, where appro-
priate source control may be more important than the specific
antibiotic class, duration of therapy, or the optimization of
antimicrobial concentrations.
Although previous literature have reported differences in
pharmacokinetics and pharmacodynamics between obese and
normal weight patients, the clinical implications of these
differences are largely unknown, because of a lack of well-
designed studies to evaluate the effect of obesity on outcomes.
Although differences in antimicrobial PK or PD among obese
patients would seemingly support greater dosing or longer
duration of treatment versus normal weight patients, our
findings challenge this concept for patients with cIAI by
demonstrating comparable clinical outcomes under current
antimicrobial dosing parameters.
On the other hand, an inverse relation between obesity
and death has been identified in surgical ICUs [9], elective
general surgery [10], pneumonia [11], heart failure, coro-
nary heart disease, and patients with diabetes mellitus. Si-
milarly, this finding of the ‘‘obesity paradox’’ was identified
in patients with surgical peritonitis with improved short-
term but not long-term outcomes [12]. In contrast, our
current study did not find evidence of the obesity paradox.
This may, in part, be related to the requirement for adequate
source control of cIAI to be achieved for enrollment in this
clinical trial. Our results suggest that antimicrobial dosing
strategies may not require adjustment for obesity in the
treatment of cIAI.
Table 3. Source Control Procedure and Clinical Outcomes Stratified by Obesity Status
Risk factor n Non-obese Obese p
Source control procedure
Resection with proximal diversion 64 11.6% 13.6% 0.49
Resection with anastomic closure 133 26.3% 24.8% 0.69
Simple closure 32 4.1% 9.6% 0.01
Percutaneous drainage 172 36.7% 27.8% 0.04
Open/surgical drainage 109 20.1% 22.7% 0.47
Diversion and drainage without resection 7 1.3% 1.5% 0.80
Outcomes
Surgical site infection 40 6.9% 9.1% 0.36
Recurrent intra-adbominal infection 76 13.8% 16.2% 0.46
Death 5 0.9% 1.0% 1.00
Composite outcome 113 19.8% 25.3% 0.14
STOP-IT group—4 d 55 18.7% 25.5% 0.19
STOP-IT group—clinical resolution 58 20.7% 25.0% 0.42
Table 4. Treatment Failure by Antibiotic Class Stratified by Obesity Status
Antibiotic class n Non-obese Obese p
b-Lactams-penicillins 312 19.6% 26.3% 0.17
Fluoroquinolones 177 19.8% 26.2% 0.33
Nitroimidazoles 163 21.3% 27.3% 0.39
Glycopeptides (vancomycin) 128 26.9% 32.0% 0.54
b-Lactams-cephalosporins 81 22.2% 16.7% 0.53
Carbapenems 75 27.5% 25.7% 0.86
Triazoles 75 18.5% 46.9% 0.01
Lincosamides 11 37.5% 0.0% 0.49
Macrolides 7 20.0% 0.0% 1.00
Lipopeptides 6 50.0% 100.0% 0.47
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Despite the increasing prevalence of obesity and the known
associations between obesity and infectious disease, includ-
ing surgical infections, the dosing of antibiotics in overweight
patients remains ‘‘as much an art as a science’’ given the
absence of evidence-based dosing strategies [13,14]. Pre-
vailing uncertainty about the need to alter pharmaceutical
dosing strategies in the obese results in large part from the
lack of drug studies evaluating dosing recommendations in
the obese, which are not required of drug manufacturers by
the Food and Drug Administration [2]. As a result, the bulk of
existing research evaluates alterations in PK and PD in the
obese, rather than clinical efficacy.
The effectiveness of antimicrobial therapy depends on
achieving therapeutic concentrations to enable pathogen
elimination while limiting toxicity. Various physiological and
pharmacokinetic parameters are altered in the obese patient,
which may impact the efficacy and toxicity of antimicrobial
agents. Delays in gastric emptying have been reported to occur
in the obese that may affect drug absorption, although most
evidence suggests this effect is not sizeable [15]. The volume
of distribution (Vd), which represents the degree to which a
drug distributes in plasma volume and tissues, may be in-
creased versus lean comparators, thus resulting in lower con-
centrations. This phenomenon is magnified for lipophilic
medications, which tend to more readily distribute than hy-
drophilic drugs. Previous work has identified larger Vd in
obese patients for most classes of antimicrobial agents, in-
cluding penicillins, cephalosporins, carbapenems, aminogly-
cosides, vancomycin, and others [16–25]. The extent to which
a medication is protein-bound also affects Vd, and obesity has
been shown to alter lipoproteins and alpha1-acid glycoprotein
[2]. Physiologic changes in the liver, including fatty infiltration
and altered cytochrome P450 activity, may also impact drug
metabolism [15]. Similarly, baseline renal clearance is gen-
erally increased in obesity because of concomitant increases in
cardiac output and blood volume that result in elevated glo-
merular filtration rate, although the presence of commonly
associated conditions such as hypertension may reverse this
phenomenon by causing chronic renal disease [2,26].
Considering the scope of potential physiologic alterations
affecting drug absorption, distribution, metabolism, and elim-
ination in obesity, it is not surprising that many studies report
pharmacokinetic differences in obese versus normal weight
patients. For example, at least 11 pharmacokinetic studies of
aminoglycosides have been conducted in human beings, most
of which support dose adjustment in obesity using adjusted
body weight [2]. Similarly, most studies of vancomycin phar-
macokinetics support weight-based dosing adjustments using
actual bodyweight [2]. In general, pharmacokinetic studies that
have observed increases in Vd and renal clearance among obese
patients have described suboptimal antimicrobial concentra-
tions in blood and tissues, thus supporting weight-based dosing
adjustments [27].
Unfortunately, few studies have evaluated the clinical im-
plications of altered pharmacokinetics for cIAI or, for that
matter, any infectious disease. A recent population-based co-
hort study of Canadian outpatients treated with antibiotics for
infection reported obesity as a predictor of treatment failure,
defined as any additional antibiotic prescriptions or hospitali-
zation for infections within 30 d of the initial therapy [27].
These findings led the authors to hypothesize that antimicrobial
dosing adjustments may be required to achieve therapeutic
concentrations in obese patients because of the pharmacoki-
netic differences earlier described. In a post-hoc subgroup
analysis of the effect of obesity on antibiotic treatment failure
in patients with cIAI who had undergone intervention to
achieve source control, greater failure rates were reported
among obese versus normal weight patients, although the dif-
ferences were not substantial and the data were limited by a
small sample of obese patients [28]. These limited data reflect a
glaring absence of evidence that requires further investigation.
The strengths of this study are its relatively large sample
size and well-matched study groups. This study has several
important limitations. First, this post-hoc analysis was per-
formed on data generated by the STOP-IT trial for which
obesity was not a pre-defined subgroup. Thus, these results
must be interpreted with caution and with recognition of the
limitations associated with post-hoc analyses. Second, al-
though the STOP-IT trial required that antimicrobial therapy
adhere to published guidelines from the Surgical Infection
Society and the Infectious Diseases Society of America [29],
the specific dosing of antimicrobial therapy was not reported.
Therefore, any off-label weight-based dosing for obese pa-
tients would not be accounted for in our analysis, although the
extent of this practice is presumably limited as it would di-
verge from consensus guidelines [29]. Finally, despite the
size of this study, the potential for type II error must be
acknowledged, particularly with respect to conclusions about
the efficacy of specific antibiotic classes that were only rarely
administered in the STOP-IT trial. In addition, it should be
recognized that type II error may explain the failure to
Table 5. Results of Multivariable Logistic
Regression for Treatment Failurea
Variable Wald w2
Odds of treatment
failure (95% CI) p
Obesity 3.8 1.55 (0.999–2.41) 0.0501
Age 0.5 0.99 (0.98 –1.01) 0.48
Male gender 0.02 1.03 (0.67 –1.60) 0.89
APACHE II 4.8 1.04 (1.00 –1.08) 0.03
Control treatment
group
0.31 1.13 (0.74 –1.74) 0.58
Diabetes mellitus 2.6 0.57 (0.28 –1.10) 0.11
Healthcare-associated
infection
1.67 0.7 (0.39 –1.19) 0.20
Hospital-acquired
infection
2.6 1.63 (0.89 –2.94) 0.11
Chronic steroid use 4.26 2.32 (1.02 –5.09) 0.04
Chronic kidney
disease
0.64 1.48 (0.53 –3.76) 0.42
ac-statistic = 0.64
APACHE =Acute Physiology and Chronic Health Evaluation.
Table 6. Association of Obesity and Treatment
Failure at BMI Thresholds
Obesity
threshold Wald w2
Odds of treatment
failure p
BMI ‡30 3.8 1.55 (0.999–2.41) 0.0501
BMI ‡35 1.3 1.35 (0.79 –2.28) 0.26
BMI ‡40 1.7 1.58 (0.77 –3.09) 0.19
BMI=Body mass index.
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demonstrate obesity as an independent predictor for treat-
ment failure. Nevertheless, these results are reassuring that
conventional treatment for cIAI does not result in large
failure rates among obese patients.
In summary, obese patients with cIAI and adequate source
control have similar outcomes as more lean comparators.
These results suggest that current antimicrobial regimens in
this specific patient population are efficacious in obese pa-
tients and may not require weight-based modification beyond
existing practice; however, these conclusions should be in-
terpreted with caution in light of the potential for type II error.
Additional studies with clinical outcomes as endpoints are
required to further evaluate the need for weight-based anti-
microbial dosing in cIAI and other infectious diseases.
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Appendix Table 1. Patient Demographics and Disease Characteristics Stratified by Obesity Status
Risk factor n Non-obese Obese p
Total 517 417 (80.7%) 100 (19.3)%
Age 53.0 [40–64] 51.5 [39–60] 0.56
Body mass index 26.0 [22–29] 40.0 [37–46] <0.001
Female 229 42.7% 51.0% 0.13
White 403 76.3% 85.0% 0.06
Black 94 19.2% 14.0% 0.23
American Indian/Alaskan Native 3 0.5% 1.0% 0.54
Asian 11 2.6% 0.0% 0.13
Hispanic 35 6.5% 8.0% 0.59
Comorbidities
Cardiac disease 70 12.7% 17.0% 0.26
Cerebrovascular disease 19 3.6% 4.0% 0.77
Peripheral vascular disease 15 3.4% 1.0% 0.32
Diabetes mellitus (total) 78 12.7% 25.0% 0.002
IDDM 36 5.0% 15.0% <0.001
NIDDM 42 7.7% 10.0% 0.44
Steroid use 31 6.5% 4.0% 0.35
Inflammatory bowel disease 53 11.5% 5.0% 0.054
Malignant disease 59 12.7% 6.0% 0.06
Chronic kidney disease 25 5.0% 4.0% 0.80
Dialysis dependence 9 1.7% 2.0% 0.69
Chronic liver disease 17 3.4% 3.0% 0.89
Chronic pulmonary disease 28 5.3% 6.0% 0.77
Rell cell transfusion since admission 43 7.9% 10.0% 0.50
IDDM= Insulin-dependent diabetes mellitus; NIDDM=Non-insulin-dependent diabetes mellitus.
Appendix Table 2. Disease Characteristics Stratified by Obesity Status
Risk factor n Non-obese Obese p
APACHE-II score 517 9.0 [ 6 –13] 8.0 [ 5 –15] 0.89
Maximum white blood cell count—per mm3 517 15.5 [11.1–19.9] 16.2 [13.1–18.9] 0.30
Maximum temperature—C 517 37.6 [37.0–38.3] 38.1 [37.3–38.5] <0.001
Total antibiotic d 517 5.0 [ 4 –9] 5.0 [ 4 – 8] 0.14
Total hospital d 517 7.0 [ 4 –11] 6.5 [ 4 –10] 0.66
STOP-IT study group 0.70
4 d 257 50.1% 48.0%
Clinical resolution 260 49.9% 52.0%
Setting of IAI
Community-acquired 321 61.2% 66.0% 0.37
Healthcare-associated 127 25.2% 22.0% 0.51
Hospital-acquired 69 13.7% 12.0% 0.66
Organ site of IAI
Colon or rectum 177 35.7% 28.0% 0.14
Biliary tree including gallbladder 56 11.0% 10.0% 0.77
Duodenum 23 5.3% 1.0% 0.10
Small Intestines 73 14.6% 12.0% 0.50
Esophagus 3 0.2% 2.0% 0.10
Stomach 31 6.0% 6.0% 1.00
Appendix 73 13.0% 19.0% 0.12
Pancreas 16 3.6% 1.0% 0.33
Liver 18 2.6% 7.0% 0.03
Abdominal wall surgical site 13 2.6% 2.0% 1.00
Other 34 5.3% 12.0% 0.01
APACHE =Acute Physiology and Chronic Health Evaluation; IAI = Intra-abdominal infection.
Appendix A: Results When Obesity Is Defined as BMI ‡ 35
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Appendix Table 3. Source Control Procedure and
Clinical Outcomes Stratified by Obesity Status
Risk factor n Non-obese Obese p
Source control procedure
Resection with proximal
diversion
64 12.0% 14.0% 0.30
Resection with anastomic
closure
133 26.9% 21.0% 0.23
Simple closure 32 5.8% 8.0% 0.40
Percutaneous drainage 172 34.3% 29.0% 0.31
Open/surgical drainage 109 19.9% 26.0% 0.18
Diversion and drainage
without resection
7 1.2% 2.0% 0.63
Outcomes
Surgical site infection 40 7.2% 10.0% 0.35
Recurrent intra-abdominal
infection
76 14.6% 15.0% 0.92
Death 5 0.7% 2.0% 0.25
Composite outcome 113 21.1% 25.0% 0.40
STOP-IT group—4 d 55 20.6% 25.0% 0.50
STOP-IT group—clinical
resolution
58 21.6% 25.0% 0.60
Appendix Table 4. Treatment Failure by Antibiotic
Class Stratified by Obesity Status
Antibiotic class n Non-obese Obese p
b-Lactams-penicillins 312 21.8% 23.3% 0.80
Fluoroquinolones 177 21.1% 28.0% 0.44
Nitroimidazoles 163 21.9% 30.7% 0.33
Glycopeptides (vancomycin) 128 27.9% 33.3% 0.60
b-Lactams-cephalosporins 81 18.8% 23.5% 0.73
Carbapenems 75 28.8% 21.7% 0.52
Triazoles 75 30.8% 30.0% 1.00
Lincosamides 11 27.3% - -
Macrolides 7 14.3% - -
Lipopeptides 6 66.7% - -
Appendix Table 5. Results of Multivariable Logistic
Regression for Treatment Failurea
Variable Wald w2
Odds of Treatment
Failure p
Obesity 1.3 1.35 (0.79–2.28) 0.26
Age 0.46 0.99 (0.98–1.01) 0.50
Male gender 0.01 1.02 (0.66–1.58) 0.92
APACHE II 4.6 1.04 (1.00–1.08) 0.03
Control treatment
group
0.19 1.1 (0.72–1.69) 0.67
Diabetes mellitus 2.3 0.59 (0.29–1.13) 0.13
Healthcare-associated
infection
1.6 0.70 (0.40–1.20) 0.21
Hospital-acquired
infection
2.5 1.61 (0.88–2.90) 0.11
Chronic steroid use 4.1 2.26 (1.00–4.97) 0.04
Chronic kidney disease 0.46 1.40 (0.50–3.51) 0.50
ac-statistic = 0.64
APACHE =Acute Physiology and Chronic Health Evaluation.
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Appendix Table 1. Patient Demographics and Disease Characteristics Stratified by Obesity Status
Risk factor n Non-obese Obese p
Total 517 466 (90.1%) 51 (9.9%)
Age 53 [40–64] 52 [39–59] 0.42
Body mass index 26.0 [23–30] 27.0 [23–33] <0.001
Female 229 43.0% 56.9% 0.06
White 403 77.0% 86.3% 0.13
Black 94 18.9% 11.8% 0.21
American Indian/Alaskan Native 3 0.4% 2.0% 0.17
Asian 11 2.40% 0.0% 0.27
Hispanic 35 0.1% 0.1% 0.75
Comorbidities
Cardiac disease 70 13.3% 15.7% 0.64
Cerebrovascular disease 19
Peripheral vascular disease 15 3.0% 2.0% 0.67
Diabetes mellitus (total) 78 13.3% 31.4% <0.001
IDDM 36 5.6% 19.6% <0.001
NIDDM 42 7.7% 11.8% 0.32
Steroid use 31 6.5% 2.0% 0.20
Inflammatory bowel disease 53 11.0% 3.9% 0.12
Malignant disease 59 12.0% 5.9% 0.19
Chronic kidney disease 25 5.0% 3.9% 0.75
Dialysis dependence 9 1.7% 2.0% 0.90
Chronic liver disease 17 3.7% 0.0% 0.16
Chronic pulmonary disease 28 5.2% 7.8% 0.42
Red blood cell transfusion since admission 43 8.6% 5.9% 0.50
IDDM= Insulin-dependent diabetes mellitus; NIDDM=Non-insulin-dependent diabetes mellitus.
Appendix Table 2. Disease Characteristics Stratified by Obesity Status
Risk factor n Non-obese Obese p
APACHE-II score 517 9 [ 6 –13] 10 [ 6 –16] 0.22
Maximum white blood cell count 517 15.6 [11.4–19.7] 15.1 [12.5–18.7] 0.91
Maximum temperature 517 37.6 [37.0–38.3] 38.2 [37.6–38.6] <0.001
Total antibiotic d 517 5.0 [ 4 – 9] 5 [ 4 – 8] 0.17
Total hospital d 517 7.0 [ 4 –11] 7.0 [ 5 –11] 0.57
STOP-IT study group 0.28
4 d 257 48.8% 56.9%
Clinical resolution 260 51.2% 43.1%
Setting of IAI
Community-acquired 321 61.9% 62.8% 0.91
Healthcare-associated 127 24.5% 25.5% 0.88
Hospital-acquired 69 13.6% 11.8% 0.72
Organ Site of IAI
Colon or rectum 177 35.1% 25.5% 0.17
Biliary tree including gallbladder 56 10.8% 11.8% 0.83
Duodenum 23 5.0% 0.0% 0.10
Small intestines 73 14.0% 15.7% 0.74
Esophagus 3 0.4% 2.0% 0.17
Stomach 31 5.8% 7.8% 0.56
Appendix 73 14.0% 15.7% 0.74
Pancreas 16 3.2% 2.0% 0.62
Liver 18 3.4% 3.9% 0.86
Abdominal wall surgical site 13 2.6% 2.0% 0.79
Other 34 5.8% 13.7% 0.03
IAI= Intra-abdominal infection; APACHE =Acute Physiology and Chronic Health Evaluation.
Appendix B: Results When Obesity Is Defined as BMI ‡ 40
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Appendix Table 3. Source Control Procedure and
Clinical Outcomes Stratified by Obesity Status
Risk factor n Non-obese Obese p
Source control procedure
Resection with proximal
diversion
64 11.8% 17.7% 0.23
Resection with anastomic
closure
133 26.7% 17.7% 0.16
Simple closure 32 5.8% 9.8% 0.26
Percutaneous drainage 172 33.1% 33.3% 0.98
Open/surgical drainage 109 21.1% 21.6% 0.93
Diversion and drainage
without resection
7 1.5% 0.0% 0.38
Outcomes
Surgical site infection 40 7.5% 9.8% 0.56
Recurrent intra-adbominal
infection
76 14.2% 19.6% 0.30
Death 5 0.9% 2.0% 0.45
Composite outcome 113 21.3% 27.5% 0.31
STOP-IT group—4 d 55 20.3% 31.0% 0.18
STOP-IT group—Clinical
resolution
58 22.3% 22.7% 0.96
Appendix Table 4. Treatment Failure
by Antibiotic Class Stratified by Obesity Status
Antibiotic class n Non-obese Obese p
b-Lactams-penicillins 312 21.9% 24.1% 0.78
Fluoroquinolones 177 21.2% 36.4% 0.24
Nitroimidazoles 163 22.8% 30.8% 0.52
Glycopeptides (vancomycin) 128 29.7% 23.5% 0.60
b-Lactams-cephalosporins 81 18.9% 28.6% 0.54
Carbapenems 75 26.7% 26.7% 1.00
Triazoles 75 31.3% 25.0% 0.71
Lincosamides 11 27.3% - -
Macrolides 7 14.3% - -
Lipopeptides 6 66.7% - -
Appendix Table 5. Results of Multivariable
Logistic Regression for Treatment Failurea
Variable Wald w2
Odds of treatment
failure p
Obesity 1.7 1.58 (0.77–3.09) 0.19
Age 0.36 1.00 (0.98–1.01) 0.55
Male gender 0.02 1.03 (0.67–1.59) 0.89
APACHE II 4.2 1.04 (1.00–1.08) 0.04
Control treatment
group
0.25 1.12 (0.73–1.72) 0.61
Diabetes mellitus 2.48 0.58 (0.28–1.11) 0.12
Healthcare-associated
infection
1.65 0.7 (0.40–1.19) 0.20
Hospital-acquired
infection
2.56 1.62 (0.89–2.91) 0.11
Chronic steroid use 4.25 2.31 (1.02–5.08) 0.04
Chronic kidney disease 0.51 1.42 (0.51–3.55) 0.48
ac-statistic = 0.64
APACHE =Acute Physiology and Chronic Health Evaluation.
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